Alpha 2.0
Login Register
» Articles » PMID: 37326291

Dupilumab As a Novel Therapy for Epidermolysis Bullosa Pruriginosa

Overview
Journal Int J Dermatol
Specialty Dermatology
Date 2023 Jun 16
PMID 37326291
Authors
Lei Shao
Dao-Qing Zhong
Yu-Mei Liu
Jian-Qin Wang
Affiliations
Soon will be listed here.
Citing Articles

Real-world experience of using dupilumab and JAK inhibitors to manage pruritus in epidermolysis bullosa pruriginosa.

Hou P, Aala Jr W, Tu W, McGrath J, Hsu C Skin Health Dis. 2024; 4(5):e445.

PMID: 39355753 PMC: 11442062. DOI: 10.1002/ski2.445.

Novel variant c.7795-1G>A of COL7A1 gene in a 12-month-old female child with recessive dystrophic epidermolysis bullosa treated with dupilumab.

Caroppo F, Cassalia F, Milan E, Belloni Fortina A JAAD Case Rep. 2024; 50:79-81.

PMID: 39070923 PMC: 11276923. DOI: 10.1016/j.jdcr.2024.06.003.